检索结果-南通市图书馆

GOECP/SEOR radiotherapy guidelines for thymic epithelial tumours

World Journal of Clinical Oncology 2021年第4期12卷 195-216页

作者： Mikel Rico Sonia Flamarique cristina casares Tamara García Miriam López Maribel Martínez Javier Serrano Manuel Blanco Raúl Hernanz Lourdes de Ingunza-Barón Francisco JoséMarcos Felipe Couñago Department of Radiation Oncology Complejo Hospitalario de NavarraPamplona 31008NavarraSpain Health Research Institute of Navarre(IdiSNA) Navarra BiomedPamplona 31008NavarraSpain Department of Radiation Oncology University Hospital Miguel ServetZaragoza 50009AragónSpain Department of Radiation Oncology University Hospital of CaceresCáceres 10004ExtremaduraSpain Department of Radiation Oncology Hospital Universitario de FuenlabradaFuenlabrada 28942MadridSpain Department of Radiation Oncology Hospital Clínico Universitario Lozano BlesaZaragoza 50009AragónSpain Department of Radiation Oncology Clínica Universidad de NavarraMadrid 28027Spain Department of Radiation Oncology Hospital Universitario TorrecárdenasAlmería 04009AndalucíaSpain Department of Radiation Oncology Hospital Universitario Ramón y CajalMadrid 28034Spain Department of Radiation Oncology Hospital Universitario Puerta del MarCádiz 11009AndalucíaSpain Department of Radiation Oncology Hospital Universitario Quirónsalud MadridHospital La LuzUniversidad Europea de MadridMadrid 28223Spain

Thymic epithelial tumours(TET)are rare,heterogeneous neoplasms that range from resectable indolent tumours to aggressive thymic carcinomas with a strong tendency to *** pathological diagnosis is complex,in part due to the management of TETs is scant and mainly based on non-randomised studies and retrospective ***,the clinical management of TETs tends to be highly heterogenous,which makes it difficult to improve the evidence *** role of technological advances in the field of radiotherapy and new systemic therapies in the treatment of TETs has received little attention to *** the present clinical guidelines,developed by the GOECP/SEOR,we review recent developments in the diagnosis and classification of *** also present a consensus-based therapeutic strategy for each disease stage that takes into consideration the best available *** guidelines focus primarily on the role of radiotherapy,including recent advances,in the management of *** main aim of this document is to promote the standardisation of clinical practice and lay the foundations for future studies to clarify the main unresolved questions related to the optimal management of TET.

关键词： Targeted therapies Thymic epithelial tumors Radiotherapy Reirradiation Guidelines Chemotherapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Integration of molecular testing for the personalized management of patients with diffuse large B-cell lymphoma and follicular lymphoma

引用

World Journal of Clinical Oncology 2023年第4期14卷 160-170页

作者： Ruth Stuckey Hugo Luzardo Henríquez Haridian de la Nuez Melian JoséCarlos Rivero Vera cristina Bilbao-Sieyro María Teresa Gómez-casares Department of Hematology Hospital Universitario de Gran Canaria Dr.NegrínLas Palmas 35019Spain Department of Anatomical Pathology Hospital Universitario de Gran Canaria Dr.NegrínLas Palmas 35019Spain Department of Hematology Hospital Universitario de Gran Canaria Dr.NegrinLas Palmas de Gran Canaria 35019Las Palmas de Gran CanariaSpain Department of Morphology Universitario de Las Palmas de Gran CanariaLas Palmas 35001Spain Medical Science Universitario de Las Palmas de Gran CanariaLas Palmas 35001Spain

Diffuse large B-cell lymphoma(DLBCL)and follicular lymphoma(FL)are the most common forms of aggressive and indolent lymphoma,*** majority of patients are cured by standard R-CHOP immunochemotherapy,but 30%–40%of DLBCL and 20%of FL patients relapse or are refractory(R/R).DLBCL and FL are phenotypically and genetically hereterogenous B-cell *** date,the diagnosis of DLBCL and FL has been based on morphology,immunophenotyping and ***,next-generation sequencing(NGS)is widening our understanding of the genetic basis of the B-cell *** this review we will discuss how integrating the NGS-based characterization of somatic gene mutations with diagnostic or prognostic value in DLBCL and FL could help refine B-cell lymphoma classification as part of a multidisciplinary pathology *** will also discuss how molecular testing can identify candidates for clinical trials with targeted therapies and help predict therapeutic outcome to currently available treatments,including chimeric antigen receptor T-cell,as well as explore the application of circulating cell-free DNA,a non-invasive method for patient *** conclude that molecular analyses can drive improvements in patient outcomes due to an increased understanding of the different pathogenic pathways affected by each DLBCL subtype and indolent FL vs R/R FL.

关键词： Next-generation sequencing Prognosis Molecular analysis Targeted therapy Chimeric antigen receptor T-cell therapy Personalized medicine

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia

引用

World Journal of Clinical Oncology 2020年第12期11卷 996-1007页

作者： Ruth Stuckey Juan Francisco López-Rodríguez Santiago Sánchez-Sosa Adrián Segura-Díaz Nuria Sánchez-Farías cristina Bilbao-Sieyro María Teresa Gómez-casares Department of Hematology Hospital Universitario de Gran Canaria Dr.NegrínLas Palmas de Gran Canaria 35019Spain

Clinical trials have demonstrated that some patients with chronic myeloid leukemia(CML)treated for several years with tyrosine kinase inhibitors(TKIs)who have maintained a molecular response can successfully discontinue treatment without *** free remission(TFR)can be reached by approximately 50%of patients who *** having similar levels of deep molecular response and an identical duration of treatment,the factors that influence the successful discontinuation of CML patients remain to be *** this review we will explore the factors identified to date that can help predict whether a patient will successfully achieve *** will also discuss the need for the identification of predictive biomarkers associated with a high probability of achieving TFR for the future personalized identification of patients who are suitable for the discontinuation of TKI treatment.

关键词： Biomarkers Tyrosine kinase inhibitors Treatment discontinuation Molecular monitoring Duration of therapy Leukemia Myelogenous Chronic BCR-ABL positive

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：